This is a strong medicine used to treat certain types of cancer, like brain tumors. It works by damaging cancer cells. It's a powerful drug and needs careful monitoring.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Carmustine is a chemotherapy medicine used for certain cancers of the brain, blood and lymph system. It comes in two very different forms. Carmustine injection, sold as BiCNU and as generic versions, is given into a vein. It is approved for several types of brain tumor, including glioblastoma, astrocytoma, medulloblastoma and tumors that have spread to the brain from elsewhere; for multiple myeloma (a cancer of plasma cells in the bone marrow) together with the steroid prednisone; and for Hodgkin and non-Hodgkin lymphoma that has come back or not responded to earlier treatment, combined with other cancer drugs. Gliadel is a wafer form of carmustine that a neurosurgeon places directly in the brain. It is used for high-grade glioma, a fast-growing brain tumor, either at first diagnosis alongside surgery and radiation or when glioblastoma returns and is operated on again. Carmustine injection is also widely used at high doses in a four-drug combination called BEAM (carmustine with etoposide, cytarabine and melphalan), which prepares people with lymphoma for a stem cell transplant using their own previously collected cells. This is an established practice rather than a labeled use.
Carmustine belongs to a group of chemotherapy drugs called alkylating agents, and to a subgroup called nitrosoureas. It attaches chemical groups to DNA, the genetic material cells need to copy themselves, and damages it so that dividing cancer cells cannot grow and multiply properly. It also affects proteins inside the cell, and its full mechanism is not completely understood. Because it passes into brain tissue, it has long been used for brain tumors. The same damage affects healthy cells that divide often, particularly the bone marrow cells that make blood, which explains its main side effects. The Gliadel wafer takes a different route: it slowly dissolves in the space left after a tumor is removed, releasing carmustine into the surrounding brain tissue, where remaining tumor cells are most likely to be, instead of sending it through the whole body.
Carmustine injection is given only in a hospital or cancer center. It is dripped slowly into a vein over at least two hours, because a faster infusion can cause burning along the vein and intense flushing. Medicine to prevent nausea is given beforehand. A course is usually repeated no more often than every six weeks, either as one dose or split over two days. The dose is calculated from body size and adjusted according to how low blood counts fell after the previous course, and the next course waits until counts have recovered. Gliadel is not a separate treatment visit. During brain surgery, after the tumor is removed, the surgeon places up to eight wafers against the walls of the cavity. They dissolve on their own, and repeat implantation has not been studied.
With the injection, nausea and vomiting are common, especially on the day of treatment. Flushing, red eyes and discomfort at the infusion site can occur during the drip. Hair loss can occur. The most important effect is a delayed drop in blood counts. Platelets, which help blood clot, usually fall about four weeks after a dose, and white blood cells, which fight infection, about five to six weeks after. This timing means problems can appear well after the infusion day. Call the care team right away for fever, chills or a sore throat; unusual bruising or bleeding; or black or bloody stools or vomit. Carmustine can also damage the lungs, through inflammation or scarring. The risk rises with higher total doses over time and with existing lung disease, and the damage can appear during treatment or many years later; people treated as children have died of lung scarring years afterward. Call the care team promptly about new shortness of breath, especially with activity, a dry hacking cough or fast, shallow breathing. Kidney and liver problems are less common and are watched for with blood tests. With Gliadel, the side effects mainly arise from surgery and the wafer's local effect. Seizures are common in the days after the operation, and brain swelling, slow wound healing, leaking of spinal fluid and meningitis (infection or inflammation of the brain's lining) can occur. A seizure, severe or worsening headache, new confusion or weakness, fever with a stiff neck, or fluid draining from the wound needs urgent medical attention.
A few medicines change how carmustine behaves. Cimetidine, an acid-reducing medicine available over the counter, can deepen the drop in blood counts. Phenobarbital, a seizure and sedative medicine, may speed carmustine's breakdown and weaken its effect. Carmustine can in turn lower blood levels of phenytoin, a seizure medicine, which matters for people with brain tumors who rely on it. The cancer team will usually suggest alternatives, so it helps to share a full list of medicines and supplements. Carmustine can harm a developing baby. Women who could become pregnant are advised to use highly effective contraception during treatment and for at least six months afterward, and men with partners who could become pregnant for at least three months. Breastfeeding is stopped during treatment. Like other nitrosoureas, carmustine is linked to a small long-term risk of a second cancer, such as leukemia, years after treatment, which is one reason survivors stay in long-term follow-up.
Treatment with the injection follows a six-week rhythm: an infusion, several weeks of blood count checks (usually weekly), and a decision about the next course once counts recover. The weeks when counts are lowest, roughly a month after each dose, are when infection and bleeding risk peak, so people are often advised to take extra care with infection exposure during that window. Breathing tests are done before starting and repeated during treatment, and kidney and liver blood tests are checked along the way. The benefit depends heavily on the cancer being treated, and for most approved uses carmustine is aimed at controlling the disease and relieving symptoms rather than cure. In the main trial of Gliadel for newly diagnosed high-grade glioma, people who received the wafers lived a median of about 14 months compared with about 12 months with placebo wafers, a modest gain. The response is judged with scans and the course of symptoms. Because lung damage can show up long after treatment ends, it is worth telling any future doctor about past carmustine treatment and reporting new breathing problems even years later.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Carmustine, what you've noticed, or ask the community a question.